// App-Quantinova.ai

2526 : A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.

Researchers

Presenter

  • Ben Markman

Principal Investigators

  • Paul L. De Souza

  • Elizabeth Claire Dees

  • Tara C. Gangadhar

  • Adam Cooper

  • Aflah Roohullah

  • Vishal Boolell

  • William Zamboni

  • Curran Murphy

  • Adrian Mario Senderowicz

  • Hong Wei Wang

Medical Centers

  • Monash Medical Centre, Melbourne, Australia

  • University of Western Sydney School of Medicine, Sydney, Australia

  • Unv of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, NC

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Unv of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, NC

  • Cerulean Pharma Inc, Waltham, MA

  • Cerulean Pharma Inc., Cambridge, MA

  • Cerulean Pharma Inc, Waltham, MA

Locations

  • United States

  • Australia

Companies

  • Cerulean Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02380677

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved